Improving outcomes for patients with hip osteoarthritis: The Hip Injection Trial (HIT)

Not Applicable

Completed

• Conditions: Osteoarthritis of the hip; Musculoskeletal Diseases

• Registration Number: ISRCTN50550256
• Lead Sponsor: Keele University

Brief Summary

2018 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/30021588 protocol 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35387783/ (added 18/08/2023) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37905905/ qualitative interview data (added 01/11/2023) 2023 Results article in https://doi.org/10.1093/rheumatology/kead659 Cost-effectiveness (added 13/12/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-07-28
• Study Completion: 2019-05-31
• Last Update Posted: 8 January 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 199

Inclusion Criteria

1. Male or female aged =40 years
2. A clinical diagnosis of unilateral or bilateral hip OA, and confirmed on plain radiography within the last 24 months, as made by a trained clinician in the musculoskeletal service
3. Moderate to severe current hip pain
4. Symptom duration of episode of at least 6 weeks
5. Hip pain occurring on most days of the last month
6. Informed written consent provided by the patient

Exclusion Criteria

1. Hip pain due to other disorders (e.g. trochanteric bursitis, avascular necrosis, pain referred from back)
2. Intra-articular corticosteroid injection into the affected hip or ipsilateral trochanteric bursa injection within the preceding 3 months
3. Any previous surgery on the affected hip
4. Clinical suspicion of local or systemic sepsis or infection
5. Current or previous infection of the affected hip
6. Significant trauma to the affected hip requiring immobilisation in the previous 3 months
7. Unwillingness to undergo study interventions
8. Unable to understand and complete self-report questionnaires written (or spoken) in English
9. Significant illness (known or suspected) including, but not limited to:
9.1. Inflammatory joint disease (e.g. rheumatoid arthritis, seronegative spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive arthritis, inflammatory-bowel disease associated inflammatory arthritis))
9.2. Polymyalgia rheumatica or other condition requiring regular oral steroid use
9.3. Malignancy (where malignancy is thought to be causing hip pain e.g. suspected bony metastases)
9.4. Any other severe medical illness which in the opinion of the local Principal Investigator (or other authorised clinical delegate) precludes trial participation
10. Pregnant or lactating females
11. Receiving anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban or low molecular weight heparin)
12. Any history of hypersensitivity to triamcinolone acetonide or 1% lidocaine hydrochloride or any of their excipients (1N Hydrochloric Acid QS, 1N Sodium Hydroxide QS, Benzyl alcohol. Polysorbate 80, Sodium carboxymethylcellulose and Sodium chloride)
13.Contraindications to use of local anaesthetic: Complete heart block and hypovolaemia

Study & Design

• Study Type: Interventional
• Study Design: Not specified